Mon panier

Human CD27 Ligand / CD70 Protein, Llama IgG2b Fc Tag, low endotoxin

Avis des utilisateurs
Numéro de produit/spécification
Prix
Qté
CDL-H5255-100ug
$390.00
CDL-H5255-1mg (500ug X 2)
$2575.00
ETA of in-stock products:2 business days
Total des articles Montant du produit$ 0

Détails du produit

  • Synonyms

    CD70, CD27LG, TNFSF7, TNFSF7G, CD27L

  • Source

    Human CD27 Ligand, Llama IgG2b Fc Tag (CDL-H5255) is expressed from human 293 cells (HEK293). It contains AA Ser 52 - Pro 193 (Accession # NP_001243.1).

    Predicted N-terminus: Glu

  • Molecular Characterization

    This protein carries a llama IgG2b Fc tag at the N-terminus.

    The protein has a calculated MW of 75.5 kDa. The protein migrates as 140-160 kDa under non-reducing (NR) condition (SDS-PAGE) due to glycosylation.

  • Endotoxin

    Less than 0.01 EU per μg by the LAL method / rFC method.

  • Purity

    >95% as determined by SDS-PAGE.

  • Formulation

    Lyophilized from 0.22 μm filtered solution in 50 mM Tris, 100 mM Glycine, 25 mM Arginine, 150 mM NaCl, pH7.5 with trehalose as protectant.

    Contact us for customized product form or formulation.

  • Reconstitution

    Please see Certificate of Analysis for specific instructions.

    For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

  • Storage

    For long term storage, the product should be stored at lyophilized state at -20°C or lower.

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. -20°C to -70°C for 12 months in lyophilized state;
    2. -70°C for 3 months under sterile conditions after reconstitution.
  • ACRO Quality Management System

    1. QMS(ISO, GMP)
    2. Quality Advantages
    3. Quality Control Process

Les clients ont également consulté

Affichage des données

  • SDS-PAGE

    CD27 Ligand SDS-PAGE

    Human CD27 Ligand, Llama IgG2b Fc Tag on SDS-PAGE under non-reducing (NR) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.

  • Bioactivity-ELISA

     CD27 Ligand ELISA

    Immobilized Human CD27 Ligand, Llama IgG2b Fc Tag (Cat. No. CDL-H5255) at 2 μg/mL (100 μL/well) can bind Human CD27, His Tag (Cat. No. CD7-H522b) with a linear range of 4-63 ng/mL (QC tested).

    Protocol
  •  CD27 Ligand ELISA

    Immobilized Human CD27 Ligand, Llama IgG2b Fc Tag (Cat. No. CDL-H5255) at 2 μg/mL (100 μL/well) can bind Biotinylated Human CD27, Fc,Avitag (Cat. No. TN7-H82F6) with a linear range of 0.3-20 ng/mL (Routinely tested).

    Protocol

Avis des utilisateurs
Publier un commentaire

Introduction de fond

Cluster of Differentiation 70 (CD70) is also known as CD27 ligand (CD27L / CD27LG), TNFSF7, TNFSF7G, is a type II transmembrane glycoprotein belonging to the TNF superfamily (TNFSF) and is a surface antigen found on activated T-and B-lymphocytes and mature dendritic cells. Binding of CD70 to its receptor CD27 induces in priming, effector functions, differentiation and memory formation of T-cells, and thus is invloved in the biological processes including T-cell activation, the proliferation of costimulated T-cells, as well as the generation of cytolytic T-cells. CD70 on T cells provides costimulatory signals that are required for T cell proliferation, clonal expansion and the promotion of effector T cell formation. CD70 on mouse B cell has been shown to inhibit terminal differentiation of activated B cells into plasma cells and enhances commitment to memory B cell responses. CD70 induces proliferation and IFNγ production, on NK cells.

Progrès de frontière

 
Progrès du développement médicamenteux
  • Nom anglais:

    CD70 antigen

  • Catégorie:

  • Nombre de médicaments répertoriés:

    0 Détails

  • Nombre de médicaments cliniques:

    37 Détails

  • Étape de développement la plus élevée:

    Phase 2 Clinical

Drug Candidate Licensing
More
  • Informations de base sur le produit
  • Détails du produit
  • Les clients ont également consulté
  • Affichage des données
  • Avis des utilisateurs
  • Contexte